絞り込み

16424

広告

こんぴら歌舞伎へ 八代目中村芝翫さんが意気込み (NHK)

香川県琴平町にある国内最古の芝居小屋で毎年春に行われる「四国こんぴら歌舞伎大芝居」の製作発表の会見が24日、東京で開かれ、襲名披露の公演となる八代目中村芝翫さん...

  1. ~日本とベトナム 再生医療技術協力が拡大...
  2. 「火山は日本にとって恵みだ」。 知の巨人...
  3. 乾癬治療、新しい飲み薬が四半世紀ぶり登場...
  4. 太地町イルカ追い込みで姉妹都市 (デイリ...

ニュース一覧

Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomide.

著者 Lopez-Girona A , Mendy D , Ito T , Miller K , Gandhi AK , Kang J , Karasawa S , Carmel G , Jackson P , Abbasian M , Mahmoudi A , Cathers B , Rychak E , Gaidarova S , Chen R , Schafer PH , Handa H , Daniel TO , Evans JF , Chopra R
Leukemia.2012 May 3 ; ():.
この記事をPubMed上で見るPubMedで表示
この記事をGoogle翻訳上で見る Google翻訳で開く

Celgene, San Diego, California, USA.

スターを付ける スターを付ける     (701view , 0users)

Full Text Sources

Miscellaneous

Other Literature Sources

Research Materials

DF15R (CVCL_Y430)

DF15 (CVCL_Y429)

Thalidomide and the immunomodulatory drug, lenalidomide, are therapeutically active in hematological malignancies. The ubiquitously expressed E3 ligase protein cereblon (CRBN) has been identified as the primary teratogenic target of thalidomide. Our studies demonstrate that thalidomide, lenalidomide and another immunomodulatory drug, pomalidomide, bound endogenous CRBN and recombinant CRBN-DNA damage binding protein-1 (DDB1) complexes. CRBN mediated antiproliferative activities of lenalidomide and pomalidomide in myeloma cells, as well as lenalidomide- and pomalidomide-induced cytokine production in T cells. Lenalidomide and pomalidomide inhibited autoubiquitination of CRBN in HEK293 T cells expressing thalidomide-binding competent wild-type CRBN, but not thalidomide-binding defective CRBN(YW/AA). Overexpression of CRBN wild-type protein, but not CRBN(YW/AA) mutant protein, in KMS12 myeloma cells, amplified pomalidomide-mediated reductions in c-myc and IRF4 expression and increases in p21(WAF-1) expression. Long-term selection for lenalidomide resistance in H929 myeloma cell lines was accompanied by a reduction in CRBN, while in DF15R myeloma cells resistant to both pomalidomide and lenalidomide, CRBN protein was undetectable. Our biophysical, biochemical and gene silencing studies show that CRBN is a proximate, therapeutically important molecular target of lenalidomide and pomalidomide.Leukemia accepted article preview online, 3 May 2012 doi:10.1038/leu.2012.119.
PMID: 22552008 [PubMed - as supplied by publisher]
印刷用ページを開く Endnote用テキストダウンロード